NCT04439292 2026-03-18Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled